Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Temporal trends in treatment patterns and overall survival for multiple myeloma management in Taiwan using the national health insurance claims database

View Full Paper
Ask AI
Bookmark
Share

Authors

SSShih‐Pei ShenTaipei Medical University

Discussion

Loading...

Member takes

Implication

Population-based analysis shows increased reimbursement and use of daratumumab improving overall survival and reducing attrition rates in multiple myeloma treatment.

Key Points

  • To investigate temporal trends in treatment patterns and overall survival for multiple myeloma in Taiwan between 2013 and 2022.
  • Population-based study using the Taiwan National Healthcare Insurance Research database and linked Registry of Catastrophic Illness.
  • Included adult patients with newly diagnosed transplant-ineligible multiple myeloma from 2013 to 2022.
  • Overall survival was estimated using Kaplan-Meier methods and hazard ratios from a multivariate Cox regression model.
  • Data from 2151 patients with NDMM between 2013–2017 and 2643 between 2018–2022 were analyzed.
  • Significant increase in daratumumab use in second line regimens from 2.23% to 20.40%.
  • Overall survival improved with median survival increasing from 2.17 years to not reached for patients diagnosed in 2021-2022.

Cite This Study

Shih‐Pei Shen (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236d054https://doi.org/10.1182/blood-2025-8133
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Two decades of landscape change in the treatment of multiple myeloma.2026
  2. 2Survival differences in transplant ineligible multiple myeloma patients in Japan and Taiwan: Exploring the potential influence of timely and unrestricted access to novel therapies2025 · 1 citations
  3. 3Updated analysis of survival and treatment evolution in european multiple myeloma patients (2012–2023) across 7 countries from the honeur network2025
  4. 4Improved survival in patients with multiple myeloma over time: A retrospective single-center study focusing on patients aged 80 years and above2025
  5. 5P54 | EVOLVING OUTCOMES IN MULTIPLE MYELOMA REAL-WORLD PRACTICE: 30-YEARS SINGLE CENTER EXPERIENCE2026